U.S. Markets closed

Today’s Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics

NEW YORK, NY / ACCESSWIRE / April 12, 2018 / Biotech stocks Keryx and CymaBay were both flying higher in Wednesday trading on positive news. Keryx announced that it had received the 2018 Corporate Innovator Award from the National Kidney Foundation, while CymaBay announced new positive results from an ongoing study of Seladelpar.

RDI Initiates Coverage on:

Keryx Biopharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Keryx Biopharmaceuticals, Inc. shares closed up 10.27% on nearly 2.5 million shares traded yesterday. The company announced on Wednesday that it has received the 2018 Corporate Innovator Award from the National Kidney Foundation. CEO of National Kidney Foundation Kevin Longino stated, "The Corporate Innovator Award was established to recognize industry partners that advance the field of nephrology by addressing an unmet medical need, or improving upon an existing practice, therapeutic or technology. This year, we are recognizing Keryx Biopharmaceuticals for their work in developing innovative medicines for patients living with chronic kidney disease." Keryx's chief medical officer John Neylan, M.D. remarked, "Keryx is a team of approximately 200 committed people working with passion to advance the care of people living with kidney disease. We are honored to be recognized by the National Kidney Foundation with this award."

Access RDI's Keryx Biopharmaceuticals, Inc. Research Report at:

CymaBay Therapeutics, Inc. shares closed up 11.35% on about 10.9 million shares on Wednesday. The stock was one of the biggest winners yesterday after the biotech company announced positive 12-week and 26-week results from an ongoing phase-II study of Seladelpar in patients who have primary biliary cholangitis. Seladelpar (MBX-8025) is the company's most advanced internal clinical program, a potent, selective, orally active PPARδ. The presentation, which is called "Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analyses of an ongoing international, randomized, dose ranging phase 2 study" will be made by Professor Gideon Hirschfield at The International Liver CongressTM hosted by the European Association for the Study of Liver Diseases (EASL) in Paris, France (April 11-15, 2018).

Herschfield remarked, "Seladelpar continues to demonstrate an impressive level of activity that is now sustained over 26 weeks of treatment. The decreased level of pruritus that was noted in the 10 mg group, a group that demonstrated a clinically relevant level of pruritus at baseline, is particularly intriguing and needs to be confirmed in additional studies." Chief Medical Officer of CymaBay, Dr. Pol Boudes, stated, "We are thrilled to have the opportunity to share new data from our development of seladelpar for patients with PBC in a late-breaking presentation at The International Liver CongressTM. This is the third consecutive year in which seladelpar will be featured in the late-breaker category at one of the key international liver meetings. We have now firmly established doses of seladelpar with compelling efficacy and tolerability which we expect to further confirm in a Phase 3 study planned to start in the second half of the year."

Access RDI's CymaBay Therapeutics, Inc. Research Report at:

Our Actionable Research on Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and CymaBay Therapeutics, Inc. (NASDAQ: CBAY) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011



CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com